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Abstract
Although opioid-induced nausea and vomiting (OINV) is common and debilitating, its mech-
anism is still unclear. Recently, we suggested that opioids affect semicircular canal function
and that this leads to a mismatch between canal input and other sensory information during
head motion, which triggers OINV. Here, we assess if visual input is relevant for this mis-
match. In a randomized-controlled crossover study 14 healthy men (26.9±3.4 years, mean
±SD) were tested twice, once blindfolded and once with eyes open, with at least one-day
washout. The opioid remifentanil was administered intravenously (0.15 μg/kg/min) for 60
minutes. After a thirty-minutes resting period, subjects’ head and trunk were passively
moved. Nausea was rated before remifentanil start (T0), before the movement intervention
(T30) and after 60 minutes (T60) of administration. At rest (T0, T30), median nausea ratings
were zero whether subjects were blindfolded or not. Movement triggered nausea indepen-
dently of visual input (nausea rating 1.5/3.0 (median/interquartile range) in the blindfolded,
2.5/6 in the eyes-open condition, χ2(1) = 1.3, p = 0.25). As movement exacerbates OINV
independently of visual input, a clash between visual and semicircular canal information is
not the relevant trigger for OINV. To prevent OINV, emphasis should be put on head-rest,
eye-closure is less important.
Introduction
Opioids are essential in the treatment of moderate to severe pain [1], but also induce debilitat-
ing nausea and vomiting. Opioid-induced nausea and vomiting (OINV) occurs in a third of all
patients treated with morphine-equivalents [2] and is one of the main reasons for post-opera-
tive nausea and vomiting (PONV) [3]. PONV is a significant factor in complications such as
pulmonary aspiration, dehydration, and electrolyte imbalance, delaying discharge and leading
PLOS ONE | https://doi.org/10.1371/journal.pone.0173925 March 14, 2017 1 / 6
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Heuser F, Schulz C, Sağlam M, Ramaioli
C, Heuberger M, Wagner KJ, et al. (2017)
Preventing opioid-induced nausea and vomiting:
Rest your head and close your eyes? PLoS ONE 12
(3): e0173925. https://doi.org/10.1371/journal.
pone.0173925
Editor: Manabu Sakakibara, Tokai University,
JAPAN
Received: August 29, 2016
Accepted: February 28, 2017
Published: March 14, 2017
Copyright: © 2017 Heuser et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper.
Funding: This work was supported by the German
Federal Ministry of Education and Research
(Grants 01 EO 0901 and 01 EO 0914). The funder
"Scho¨n Klinik Bad Aibling" provided support in the
form of salaries for author KJ, but did not have any
additional role in the study design, data collection
and analysis, decision to publish, or preparation of
the manuscript. The specific roles of this author are
articulated in the ‘author contributions’ section.
to hospital admission after ambulatory surgery, which greatly increases health care cost [4].
PONV negatively impacts patient satisfaction [5] and patients even rank it amongst the most
distressing non-life-threatening side effects [1].
The exact mechanism of OINV is still not clear. Opioids affect vestibular function, as dem-
onstrated by a decrease in caloric response with morphine [6], a diminished active vestibulo-
ocular reflex (VOR) with pethidine and fentanyl administration [7], vestibular dysfunction
with heroin abuse [8], and decreased semicircular canal function, measured by the VOR gain,
during administration of the short-acting μ-agonist remifentanil [9,10]. Opioid receptors are
present within the VOR-three-neuron arc [11,12] and in the cerebellum [13], and could medi-
ate the changes in vestibular-ocular motor function (VOR gain). Additional oculomotor find-
ings during opioid administration, such as gaze-evoked nystagmus, saccadic smooth pursuit
and, in particular, downbeat-nystagmus, point to cerebellar involvement [7,9].
Importantly, we demonstrated that head movement greatly exacerbates nausea during
administration of the opioid remifentanil, while resting protects from it [9,14]. We suggested
that the change in semicircular canal input during remifentanil administration leads to a mis-
match between this information and that of other sensors when the head is moved, triggering
nausea and vomiting [9].
To understand the role of visual input for this mismatch and, practically, to assess whether,
in addition to avoiding head movement, it makes sense to close the eyes to decrease OINV, we
examined motion-dependent nausea during opioid administration with and without vision.
Materials and methods
Standard protocol approvals, registrations, and patient consent
Fourteen healthy men aged 26.9±3.4 years (mean±SD) gave their written consent to the study
that was approved by the Ethics Committee of Technische Universita¨t Mu¨nchen’s Medical
Faculty and performed in accordance with the Declaration of Helsinki. Subjects were free to
withdraw from the experiment at any time. They were financially remunerated for taking part
in the study. Subjects did not suffer from any balance disorders and were not taking any medi-
cation, explicitly no opioids.
Opioid administration
Remifentanil, chosen because of its well-known and controllable characteristics, was adminis-
tered intravenously (0.15 μg/kg/min, in analogy to Lehnen et al. [9]) during standard monitor-
ing (ECG, non-invasive blood pressure, pulse, pulsoxymetry).
Experimental conditions
Subjects were divided into two subgroups of equal age (26.4±3.5 and 27.3±3.6 years, mean
±SD), motion-sickness-susceptibility score (assessed by the Motion Sickness Susceptibility
Questionnaire, MSSQ-Short [15], 5.9±9.2 and 5.9±5.8 points) and postoperative-nausea-and-
vomiting risk [3] (20±9.7% and 22±8.5%). In a crossover design, each subject was tested twice
with at least one-day washout. Seven subjects were first tested “blindfolded,” then “eyes-open”,
and vice-versa. In the condition “blindfolded”, subjects wore eye patches for the entire dura-
tion of the experiment. They were resting in a semi-recumbent position during 60 minutes of
remifentanil administration (Fig 1A). After remifentanil had been administered for 30 min-
utes, subjects were bent forward and backward ten times at a frequency of 1 Hz. The condition
“eyes-open” was the same as the “blindfolded” condition, but the subjects were not blinded
and were encouraged to keep their eyes open.
Does closing your eyes prevent OINV?
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Subjects rated nausea on a scale from zero (no nausea) to ten (vomiting) before receiving
remifentanil (T0), after the period of 30 minutes rest (before being moved, T30) and after the
30 minutes following the movement intervention (T60). Maximal ratings for each period were
analysed.
Fig 1. A. Experimental design (crossover study). Subjects rested in a semi-recumbent position while remifentanil was continuously
administered intravenously. After 30 minutes, subjects were bent forward and backward ten times at a frequency of 1 Hz (“Move”) after which
they rested again for 30 minutes. Nausea was assessed on a numerical scale from 0 (no nausea) to 10 (vomiting) before the remifentanil
infusion (T0), during the 30 minutes of rest with remifentanil administration (T30), and during the 30 minutes (T60) after the movement
intervention. The study contained two conditions: in the “blindfolded” condition subjects wore an eye patch during the entire duration of the
experiment, while in the “eyes-open” condition subjects were encouraged to leave their eyes open. In a crossover design with at least one-day
of washout, seven subjects were first tested with the condition “blindfolded” and then “eyes-open”, and vice versa. B. Effects of movement on
nausea during remifentanil administration with and without visual input. Median (horizontal line), interquartile range (box) of nausea values
quantified on a numerical scale from 0 (no nausea) to 10 (vomiting) in conditions “eyes-open” (white) and “blindfolded” (grey). Crosses
designate outliers (outside 75-percentile + 1.5x interquartile range). Whiskers extend to the closest data value not considered an outlier. Data
from the two subgroups of the crossover design was pooled, as there was no difference between the subgroups in all conditions (all p>0.20).
During rest, nausea ratings did not differ at any time point (T0, T30 of both conditions; all medians zero, p = 0.26). Movement led to a marked
increase in nausea (difference between T0, T30, and T60, “blindfolded”: p = 0.012, “eyes-open”: p<0.001), independently of visual input (no
difference between nausea ratings at T60 in the "blindfolded" and "eyes-open" condition, p = 0.25)
https://doi.org/10.1371/journal.pone.0173925.g001
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Statistical analysis
Data were analysed offline in Matlab1 (Mathworks1, Natick, MA). Differences in nausea rat-
ings between subgroups were assessed with an independent samples Mann-Whitney-U test
(factor order), differences within time points T0, T30 and T60 of both conditions (“blindfolded”,
“eyes-open”) with a related samples Friedman’s ANOVA-by-ranks (significance level p<0.05).
Results
Nausea ratings did not differ between the subgroups for each time point (T0, T30, T60). There-
fore they were independent of the order of the conditions (all p>0.20), and consequently, data
for both subgroups of the crossover design were pooled. Fig 1B shows nausea ratings for the
“eyes-open” and the “blindfolded” conditions at rest (T0, T30) and during the 30 minutes after
the movement intervention (T60). At rest, nausea ratings did not differ for all times T0 and T30
of both conditions (all medians zero; χ2(3) = 4.0, p = 0.26). Comparison of T0, T30, and T60
within the conditions revealed that movement triggered nausea in both conditions (“blind-
folded”: χ2(2) = 8.9, p = 0.012, “eyes-open”: χ2(2) = 16.7,p<0.001). Nausea ratings during T60
did not differ between the conditions (χ2(1) = 1.3, p = 0.25, “eyes-open” 2.5/6.0 (median/inter-
quartile range), “blindfolded” 1.5/3.0).
Discussion
Nausea during remifentanil administration was triggered by movement and avoided by rest in
all subjects independently of visual input. This suggests that vision is not the major cause for
an inter-sensory mismatch with semicircular canal input during head motion.
Remifentanil reversibly affects vestibulo-ocular reflex function, as measured by the VOR
gain of the horizontal semicircular canals [9,10]. This altered information could clash with neck
proprioception or other vestibular sensory information. An intra-vestibular mismatch between
reduced horizontal semicircular canals [9] and not accordingly altered otolith signals seems
likely. Such an intra-vestibular mismatch is acknowledged as a causative factor for seasickness
(for review, see Bertolini&Straumann, 2016 [16]) and also seems to provoke space sickness
where altered otolith signals in weightlessness clash with regular semicircular canal input [17].
Our study confirms the head-motion dependence of OINV with a striking median of zero
on the nausea scale during rest in all conditions. As in our prior work, the incidence of OINV
in our study (57/64% or 8/9 out of the 14 subjects in the “blindfolded”/“eyes-open” conditions)
is higher than that predicted by the standard risk score[3] for post-operative nausea and vomit-
ing (21±9%, mean±SD or 3/14). This is possibly because the risk score does not control for
head movement, i.e., not all patients included in the calculation of the score might have experi-
enced perioperative movement interventions similar to the ones in our study. It should be
noted that there is a limitation to the interpretation of this exploratory approach due to the rel-
atively small sample size and the fact that only men were tested.
In conclusion, our study suggests that an intra-vestibular, and not a visual-vestibular, mis-
match that becomes apparent during movement exacerbates OINV. Resting thus protects
from OINV, while closing the eyes appears less important. Understanding this mechanism will
improve pain management with opioids. In clinical practice, especially during transient opioid
application, OINV could be reduced by avoiding head movement, e.g. with a head immobilizer
peri-operatively.
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